Brazzolotto_2021_Pharmacogenomics.J_21_165

Reference

Title : Characterization of four BCHE mutations associated with prolonged effect of suxamethonium - Brazzolotto_2021_Pharmacogenomics.J_21_165
Author(s) : Brazzolotto X , Courcelle S , Sauvanet C , Guillon V , Igert A , Kononchik J , Nachon F , Ceppa F , Delacour H
Ref : Pharmacogenomics J , 21(2):165-173 : , 2021
Abstract : Butyrylcholinesterase (BChE) deficiency is characterized by prolonged apnea after the use of muscle relaxants (suxamethonium or mivacurium) in patients who have mutations in the BCHE gene. Here, we report the characterization of four BCHE mutations associated with prolonged effect of suxamethonium (amino acid numbering based on the matured enzyme): p.20delValPheGlyGlyThrValThr, p.Leu88His, p.Ile140del and p.Arg386Cys. Expression of recombinant BCHE mutants, kinetic analysis and molecular dynamics were undertaken to understand how these mutations induce BChE deficiency. Three of the mutations studied (p.20delValPheGlyGlyThrValThr, p.Ile140del and p.Arg386Cys) lead to a "silent" BChE phenotype. Recombinant BCHE expression studies for these mutants revealed BChE activity levels comparable to untransfected cells. Only the last one (hBChE-L88H) presented BChE activity in the transfected cell culture medium. This BChE mutant (p.Leu88His) is associated with a lower k(cat) value compare to the wild-type enzyme. Molecular dynamics simulations analyses suggest that a destabilization of a structure implicated in enzyme activity (-loop) can explain the modification of the kinetic parameter of the mutated protein.
ESTHER : Brazzolotto_2021_Pharmacogenomics.J_21_165
PubMedSearch : Brazzolotto_2021_Pharmacogenomics.J_21_165
PubMedID: 33024248

Related information

Citations formats

Brazzolotto X, Courcelle S, Sauvanet C, Guillon V, Igert A, Kononchik J, Nachon F, Ceppa F, Delacour H (2021)
Characterization of four BCHE mutations associated with prolonged effect of suxamethonium
Pharmacogenomics J 21(2):165-173 :

Brazzolotto X, Courcelle S, Sauvanet C, Guillon V, Igert A, Kononchik J, Nachon F, Ceppa F, Delacour H (2021)
Pharmacogenomics J 21(2):165-173 :